Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Gene therapy trial offers hope for boys and men with rare blinding eye condition

NCT ID NCT05878860

First seen May 01, 2026 · Last updated May 23, 2026 · Updated 3 times

Summary

This study tests a gene therapy called ATSN-201 for people with X-linked retinoschisis, a rare inherited eye disease that splits the retina and can lead to vision loss. The trial includes males aged 6 and older, and aims to see if the treatment is safe and can improve vision. The study has three parts, including a phase 3 randomized controlled portion to measure changes in how well the retina senses light.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for X-LINKED RETINOSCHISIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Bascom Palmer Eye Institute

    RECRUITING

    Miami, Florida, 33136, United States

    Contact

  • Children's Hospital of Los Angeles

    RECRUITING

    Los Angeles, California, 90027, United States

    Contact

  • Children's Hospital of Philadelphia

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

    Contact

  • Oregon Health Sciences University

    RECRUITING

    Portland, Oregon, 97239, United States

    Contact

Conditions

Explore the condition pages connected to this study.